PHOTOPHARMICS, INC.

LEHI, UT · Founded 2011 · Medtech · Private

Celesté, an investigational ophthalmic device that delivers targeted light stimulation to modulate retinal and circadian signaling pathways

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · photopharmics.com

Sector: Medtech
Headquarters: LEHI, UT
Founded: 2011
Latest Form D: $16.1M, Nov 2023
Total capital: $35.3M

Federal grants: $639K; 2 awards · 2021–2024; Rank in peer group#121 of 445
Private capital raised: $34.7M; 8 Form D · last Nov 2023; 36 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 3; 5 pending · first 2021; Rank in peer group#68 of 445

Capital timeline

Latest events

Sep 2024Federal grantHealth and Human S · Phase II · Amelioration of opioid use disorder with heterodyned whole body vibration$319K
Nov 2023Private capital raisedForm D · SEC · 8th filing$16.1M
Jun 2021Federal grantHealth and Human S · Phase I · Amelioration of opioid withdrawal-induced anxiety and craving with heterodyned whole body vibration$320K
Dec 2020Private capital raisedForm D · SEC · 7th filing$2.5M
Oct 2019Private capital raisedForm D · SEC · 6th filing$6.6M
Mar 2017Private capital raisedForm D · SEC · 5th filing$2.7M
Feb 2017Private capital raisedForm D · SEC · 4th filing$2.3M
Jul 2015Private capital raisedForm D · SEC · 3rd filing$2.1M
Jan 2013Private capital raisedForm D · SEC · 2nd filing$2.1M
Nov 2012Private capital raisedForm D · SEC · 1st filing$330K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 445 peers

Line = median

Medtech · Device

Federal grants#121 · top 27%
Granted patents#68 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Kent SavageResearcherExecutive Officer, DirectorLinked by 1 patent
Daniel AdamsDirectorNamed in SEC Form D filings
Gavin ChristensenDirectorNamed in SEC Form D filings
Henry, Jr. SavageExecutive Officer, DirectorNamed in SEC Form D filings
Ted StanleyDirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 8

Apr 14, 2026GrantedLight Therapy ApparatusesUSPTOUS 12,599,779
Dec 19, 2024PendingOcular Treatments For Neurological And Neuropsychiatric DisordersUSPTOApplication 18781933
Jul 23, 2024GrantedOcular Treatments For Neurological And Neuropsychiatric DisordersUSPTOUS 12,042,471

Show all 8 patent records

Light Therapy ApparatusesApr 14, 2026 · US 12,599,779Granted
Ocular Treatments For Neurological And Neuropsychiatric DisordersDec 19, 2024 · Application 18781933Pending
Ocular Treatments For Neurological And Neuropsychiatric DisordersJul 23, 2024 · US 12,042,471Granted
Methods For Preventing And Treating Motor-related Neurological ConditionsMar 24, 2022 · Application 17544850Pending
Methods For Preventing And Treating Motor Related Neurological ConditionsDec 7, 2021 · US 11,191,478Granted
Methods For Preventing And Treating Motor-related Neurological ConditionsOct 19, 2017 · Application 15430308Pending
Apparatuses For Treating And/or Diagnosing Motor Related Neurological ConditionsApplication PCTUS2012068045Pending
Light Emitting Apparatuses For Treating And/or Diagnosing Motor Related Neurological ConditionsApplication PCTUS2012040284Pending

EndoSound, Inc.Similar federal contract value in Medtech · null in contracts
APPLIKATE TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
BREVITEST TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
PIONEAR TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
NIMA LABS, INC.Similar federal contract value in Medtech · null in contracts
DIGOSTICS LtdSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.